Improving the economics of NASH/NAFLD treatment through the use of systems biology

Drug Discovery Today

Volumn 22, Issue 10, 2017, Pages 1532-1538

  Bosley, Jim ^a   Boren, Christofer ^b   Lee, Sunjae ^b   Grøtli, Morten ^c   Nielsen, Jens ^b,d   Uhlen, Mathias ^b   Boren, Jan ^c   Mardinoglu, Adil ^b,d  

^a Clermont Bosley LLC   (United States)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC LIVER DISEASE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; GENOME; HEALTH PROGRAM; HUMAN; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; REVIEW; SYSTEMS BIOLOGY; ANIMAL; DRUG EFFECT; LIVER; PROCEDURES;

DRUG;

ANIMALS; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PHARMACEUTICAL PREPARATIONS; SYSTEMS BIOLOGY;

EID: 85026322326     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.07.005     Document Type: Review

References (52)

1. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 686–690.
2. Abdelmalek, M.F., NAFLD: the clinical and economic burden of NAFLD: time to turn the tide. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 685–686.
3. Uhlen, M., et al. Transcriptomics resources of human tissues and organs. Mol. Syst. Biol., 12, 2016, 862.
4. Yizhak, K., et al. Modeling cancer metabolism on a genome scale. Mole. Syst. Biol., 11, 2015, 817.
5. Mardinoglu, A., et al. The employment of systems biology in gastroenterology and hepatology. Nat. Rev. Gastroenterol. Hepatol., 2017 (in press).
6. Nielsen, J., Systems biology of metabolism: a driver for developing personalized and precision medicine. Cell Metab. 25 (2017), 572–579.
7. Lee, S., et al. Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab. 24 (2016), 172–184.
8. Tilg, H., et al. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14 (2017), 32–42.
9. Michelotti, G.A., et al. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665.
10. Kim, W.R., et al. OPTN/SRTR 2015 annual data report: liver. Am J. Transplant. 17:Suppl. 1 (2017), 174–251.
11. Anon, Nonalcoholic Steatohepatitis – Epidemiology Forecast to 2022., 2013, Report Linker.
12. Habka, D., et al. Future economics of liver transplantation: a 20-year cost modeling forecast and the prospect of bioengineering autologous liver grafts. PLoS One, 10, 2015, e0131764.
13. Anon. (2014) Global Non-Alcoholic Steatohepatitis (NASH) Market is Expected to Reach $1.6 Billion by 2020, Allied Market Research.
14. Anon, NASH: The Next Breakout Biotech Market. 2017, Wealth Daily.
15. Paul, S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9 (2010), 203–214.
16. Villaruz, L.C., et al. MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin. Epigenet., 7, 2015, 58.
17. Sullivan, S., Implications of diet on nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 26 (2010), 160–164.
18. Hashemi Kani, A., et al. Diet macronutrients composition in nonalcoholic fatty liver disease: a review on the related documents. Hepatitis Monthly, 14, 2014, e10939.
19. Basaranoglu, M., et al. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg. Nutr. 4 (2015), 109–116.
20. Gadkar, K., et al. Quantitative systems pharmacology: a promising approach for translational pharmacology. Drug Discov. Today Technol. 21–22 (2016), 57–65.
21. Knight-Schrijver, V.R., et al. The promises of quantitative systems pharmacology modelling for drug development. Comput. Struct. Biotechnol. J. 14 (2016), 363–370.
22. Bosley, J., et al. Systems pharmacology modeling in type 2 diabetes mellitus. Mager, D., Kimko, H., (eds.) Systems Pharmacology and Pharmacodynamics, 2016, Springer, 465–507.
23. Hodgkin, A.L., Huxley, A.F., A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 117 (1952), 500–544.
24. Guyton, A.C., et al. Circulation: overall regulation. Annu. Rev. Physiol. 34 (1972), 13–46.
25. Rodighiero, V., Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinetics 37 (1999), 399–431.
26. Ashworth, W.B., et al. A computational model of hepatic energy metabolism: understanding zonated damage and steatosis in NAFLD. PLoS Comput. Biol., 12, 2016, e1005105.
27. Fisher, C.P., et al. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 15070–15078.
28. Mardinoglu, A., Nielsen, J., Systems medicine and metabolic modelling. J. Intern. Med. 271 (2012), 142–154.
29. Mardinoglu, A., et al. Genome-scale modeling of human metabolism – a systems biology approach. Biotechnol. J. 8 (2013), 985–996.
30. Ghaffari, P., et al. Cancer metabolism: a modeling perspective. Front. Physiol., 6, 2015, 382.
31. Mardinoglu, A., Nielsen, J., New paradigms for metabolic modeling of human cells. Curr. Opin. Biotechnol. 34 (2015), 91–97.
32. Bjornson, E., et al. Personalized cardiovascular disease prediction and treatment: a review of existing strategies and novel systems medicine tools. Front. Physiol., 7, 2016, 2.
33. Uhlen, M., et al. Tissue-based map of the human proteome. Science, 347, 2015, 1260419.
34. Kim, M.S., et al. A draft map of the human proteome. Nature 509 (2014), 575–581.
35. Wilhelm, M., et al. Mass-spectrometry-based draft of the human proteome. Nature 509 (2014), 582–587.
36. Holmes, E., et al. The promise of metabolic phenotyping in gastroenterology and hepatology. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 458–471.
37. Adiels, M., et al. Kinetic studies to elucidate impaired metabolism of triglyceride-rich lipoproteins in humans. Front. Physiol., 6, 2015, 342.
38. Mardinoglu, A., et al. Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol. Syst. Biol., 9, 2013, 649.
39. Agren, R., et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol., 10, 2014, 721.
40. Frezza, C., et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477 (2011), 225–228.
41. Folger, O., et al. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol., 7, 2011, 501.
42. Varemo, L., et al. Proteome- and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes. Cell Rep. 11 (2015), 921–933.
43. Lee, S., et al. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis. Nucleic Acids Res. 44 (2016), 5529–5539.
44. Mardinoglu, A., et al. Defining the human adipose tissue proteome to reveal metabolic alterations in obesity. J. Proteome Res. 13 (2014), 5106–5119.
45. Mardinoglu, A., et al. Extensive weight loss reveals distinct gene expression changes in human subcutaneous and visceral adipose tissue. Sci. Rep., 5, 2015, 14841.
46. Mardinoglu, A., et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun., 5, 2014, 3083.
47. Mardinoglu, A., et al. Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD. Mol. Syst. Biol., 13, 2017, 916.
48. Hyötyläinen, T., et al. Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat. Commun., 7, 2016, 8994.
49. Gerstein, M.B., et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489 (2012), 91–100.
50. Peddinti, G., et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia, 2017, 10.1007/s00125-017-4325-0 Published online June 8, 2017.
51. Mardinoglu, A., et al. Plasma mannose levels are associated with incident type 2 diabetes and cardiovascular disease. Cell Metab., 26, 2017, 10.1016/j.cmet.2017.07.006.
52. Greenfield, J.R., et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am. J. Clin. Nutr. 89 (2009), 106–113.